menu
    • menu

    List of NDC API Active Pharmaceutical Ingredients supplied/manufactured by Bristol Myers Squibb

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Each day, our employees around the world work together for patients – it drives everything we do. ...
    Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Each day, our employees around the world work together for patients – it drives everything we do. We are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Bristol Myers SquibbUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    430 E. 29th Street, 14th Floor, New York, NY 10016
    Telephone
    Telephone
    +1 (212) 546 4000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bms.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/bristol-myers-squibb
    youtube
    YouTube
    Twitter
    Twitter
    https://twitter.com/BMSNEWS

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    CPhI Worldwide, Milan

    CPhI Worldwide, Milan

    Not Confirmed

    envelop Contact Supplier

    CPhI Worldwide, Milan

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    "ICE is pioneering sustainability, innovation in bile acid research for neurodegenerative diseases”

    "ICE is pioneering sustainability, innovation in bile acid research for neurodegenerative diseases”

    This week, SpeakPharma interviews Roger Viney, Chief Commercial Officer of ICE Pharma, a world-leading manufacturer of specialty biliary acid products with a focus on innovation, environmental responsibility, and a strong company culture. Viney discusses the company’s ambitious sustainability targets, and its exciting research into bile acids’ potential in treating neurodegenerative diseases like Parkinson’s.  🔑 HIGHLIGHTS// focus on innovation, environmental responsibility, and a strong company culture ICE Pharma has set four strategic pillars to guide its sustainability efforts. Can you tell us what these four pillars are and how they contribute to the long-term resilience of the business and its supply chain? In 2022, we developed a comprehensive long-term sustainability strategy, accompanied by a short-term roadmap to guide our actions over the next three years. This outlines the strategic choices that will define our way forward and details the progress we are making against our roadmap. Our sustainability strategy is designed to bolster the long-term resilience of our business and supply chain, provide a source of fulfillment for our employees and enable our customers to continue developing and delivering treatments for hepatic and neurological diseases, as well as other conditions that respond to bile acid-based therapies. By contributing holistically to a healthier society and environment, our strategy aims to create long-term value. We aim to maximize our positive impact on health by opening our Biliary Acid Library of potential new molecules to further the development of these treatments. Additionally, we strive to reduce our environmental footprint by creating products with fewer raw materials, diversifying the animal sources we use, and exploring new plant-based bile acid derivatives. We have established clear targets along four strategic pillars, supported by robust ESG governance and leadership. Firstly, we are committed to fighting illness through product innovation. By providing innovative, safe, and high-quality pharmaceutical ingredients, we help our customers build a healthier society. Secondly, we focus on accelerating sustainable operations by monitoring and reducing our emissions, energy, and water consumption through robust ESG processes and accountability. Thirdly, we prioritize building strong relationships by managing our supply chain transparently, fostering strong supplier relationships, and adhering to responsible business practices. Lastly, we are dedicated to caring for people by cultivating a transformational and inclusive culture that ensures the well-being and development of our employees. 🔑 HIGHLIGHTS// Biliary Acid Library of potential new molecules / robust ESG governance and leadership / manage our supply chain transparently ICE Pharma has committed to an ambitious sustainability plan. Can you elaborate on specific targets it has set to reduce greenhouse gas (GHG) emissions and increase the use of renewable energy? Also, what significant investments have ICE made or plans to make to support these goals? ICE’s carbon footprint aligns with industry standards in the pharmaceutical and API sectors in terms of GHG emissions. We have set an internal target that is challenging yet achievable and aligned with our business objectives – a 20 percent reduction in Scope 1 and 2 emissions (majorly energy-related) and a 30 percent reduction in Scope 3 emissions (from solvents, reagents, and animal byproducts used as raw materials) by 2033. We plan to achieve these targets through two main approaches. For electric power, we aim to achieve 100 percent renewable energy utilization by 2030, and we are well on track to achieve this. We are heavily investing in renewable sources, either through sourcing green energy or through in-house investments in photovoltaic (PV) systems at our factories. Fortunately, the significant growth in installed renewable capacity across all geographies where we operate makes this goal both achievable and financially sustainable. However, a substantial portion of our energy consumption comes from generating heat involved in our processes. To counter this, we are focusing on energy efficiency, targeting over 90 percent of our energy consumption to be covered by ISO 50001 standards, and investing heavily in more efficient technologies. For Scope 3 emissions, our efforts are concentrated on further developing our processes to reduce the amount of chemicals used, improve our yields, and switch to animal-source raw materials with a smaller carbon footprint. 🔑 HIGHLIGHTS// internal target that is challenging yet achievable / 100 percent renewable energy utilization by 2030 ICE Pharma highlights its strong company culture as one of the secrets to its success. Can you speak on how you foster a collaborative and respectful work environment, and how these efforts contribute to the company’s overall success? At ICE Pharma, we place great emphasis on building a collaborative and respectful work environment, recognizing it as a key driver of innovation and success. Our culture is fostered by our Cultural Pillars: Unity, Evolution, and Achievement. These pillars shape our approach in several key areas. Firstly, we value diversity and inclusion. Operating across different cultural contexts and geographies, we have gathered a diverse range of ethnicities. We actively ensure that all voices are represented. This promotes a culture where everyone is respected for their unique perspectives. Secondly, recognizing employee contributions is fundamental to our approach. ICE Pharma celebrates achievements and milestones, ensuring that employees feel valued. We also support professional development and personal growth of employees through initiatives such as secondments and international mentoring programs, and financial support for excellence training courses. This creates motivation and loyalty, reinforcing a positive company atmosphere. Thirdly, we understand the importance of work-life balance. We promote policies that allow employees to maintain a healthy equilibrium between their professional and personal lives, with a special focus on parenthood. This respect for individual well-being translates into a happier, more engaged workforce. By fostering these values, we create a work environment that drives productivity, encourages innovation, and strengthens the company’s overall success. 🔑 HIGHLIGHTS// value diversity and inclusion / recognize employee contributions / understand the importance of work-life balance Considering the unique properties of bile acids, can you discuss how ICE Pharma is leveraging its technology to develop innovative drug delivery systems for emerging therapies or to address challenges with existing medications? We are thrilled about the expanding role of bile acids in medicine. ICE Pharma holds a unique position, being deeply involved in fundamental research, developing new bile acids, bringing them into clinical trials, and manufacturing generic medicines based on these compounds. Recent research has highlighted the role of bile acids as metabolic regulators, revealing their potential to treat a variety of diseases. They have emerged as an excellent class of molecules for targeting metabolic conditions such as type 2 diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Bile acids are now known to act on several nuclear receptors, and it is becoming clear that their signaling properties are complex and extend beyond the FXR and TGR5 receptors, where most current research is focused. One particularly exciting area of interest is the potential of bile acids in treating neurodegenerative diseases. In collaboration with the Ferrier Institute, we have contributed to research on Parkinson’s disease. Mitochondrial dysfunction is a well-documented mechanism in both sporadic and familial Parkinson’s disease. Ursodeoxycholic acid (UDCA) has been identified as a bile acid that enhances mitochondrial function in multiple in vitro and in vivo models of Parkinson’s disease. Our studies indicate that modified novel bile acid molecules could lead to the development of more efficacious treatments that improve mitochondrial function and overall cellular health, presenting promising new therapeutic options for Parkinson’s disease. 🔑 HIGHLIGHTS// potential of bile acids in treating neurodegenerative diseases / contributed to research on Parkinson’s disease / present promising new therapeutic options Given ICE Pharma’s commitment to the highest quality and regulatory compliance standards, can you elaborate on how the company ensures that these standards are consistently maintained, especially when dealing with the complexities of animal-derived products? At ICE, we place great emphasis on controlling pathogens in our animal-derived products, ensuring safety and quality throughout the entire supply chain, from the collection of bile to the finished product. The bile is sourced exclusively from authorized countries, and each production batch is meticulously traced to certify that every animal has been raised and sacrificed according to specific guidelines. The initial step in bile processing involves a treatment that certifies the product as TSE/BSE Free. This is followed by at least two additional stages, based on experimental studies conducted by specialized laboratories, which are effective in inactivating viruses. Intermediates and the final product are handled in closed cycles or in contamination-controlled areas (ISO-8 cleanrooms). Beyond these fundamental aspects, ICE is deeply committed to keeping its dossiers up to date with the latest guidelines and constantly monitoring trends in analytical data to ensure consistent product quality. Where possible, we enhance this quality through a change control plan carefully managed by our Quality Assurance team. Staff training, predictive and preventive maintenance plans, equipment qualification, and process validation are crucial activities involving the entire workforce with the support of the Quality Unit. Our commitment to continuous improvement drives us to focus on digital globalization to ensure ever-greater transparency and reliability in the data that supports our work. As John Ruskin said, “quality is never an accident. It is always the result of intelligent effort.” We continue to follow this philosophy in our daily commitment. 🔑 HIGHLIGHTS// bile is sourced exclusively from authorized countries / each production batch is meticulously traced / ensure ever-greater transparency and reliability

    Impressions: 84

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases

    #SpeakPharma With ICE Pharma
    30 Sep 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    2024 US Elections: Harris, Trump differ on abortion rights, ACA, public health spends; agree on need to cut drug prices

    2024 US Elections: Harris, Trump differ on abortion rights, ACA, public health spends; agree on need to cut drug prices

    The US is in the midst of yet another, or perhaps the most, polarizing Presidential election. The two candidates have highly divergent personas, records, visions and views. That gets reflected in their starkly different visions for the healthcare system.Healthcare is the second most important issue for voters in the 2024 US elections, with only the economy ranking higher, according to the Pew Research Center.In this week’s PharmaFlow, we look at the past approaches of both the contenders — Democratic presidential nominee Kamala Harris and Republican contender Donald Trump — towards healthcare, and what the two presidencies could mean for the US healthcare industry.Both Harris and Trump have a rare point of agreement — that the US government should act on reducing high drug prices. But have they spelt out how they will make healthcare more accessible? Our analysis should give you some answers.Abortion remains a pivotal issue, may shape broader discussions on healthcareTrump takes pride in the fact that he played an important role in overturning Roe v. Wade, a ruling that protected the abortion rights of women across America. Trump did that by selecting Supreme Court justices who were instrumental in overturning it. Two and a half years after Roe v. Wade was overturned, Trump faces an electorate that largely seems to favor abortion rights — according to Pew Research, 63 percent respondents say abortion should be legal in all or most cases, while 36 percent say it should be illegal in all or most cases.Candidates’ stances on abortion access, including the regulation on medications like mifepristone, are being scrutinized by both supporters and opponents of abortion rights. In June this year, the US Supreme Court had unanimously rejected a case to restrict access to the abortion drug mifepristone. The demand for its ban had been raised by an anti-abortion group in Texas.Of late, there have been reports of Republicans trying to distance themselves from aggressive anti-abortion ideas coming from its party men and allies. Aiming to carve-out a political middle ground, Trump has said that abortion policy should be made by the states. Despite Trump’s softening of stance, abortion rights is likely to not only affect voter turnout, but also shape broader discussions on healthcare and women’s rights.Affordable Care Act: Harris to strengthen it, Trump has ‘concepts of a plan’ to replace itHarris has been all for expanding and strengthening the Affordable Care Act (ACA). She has promised to “make affordable healthcare a right, not a privilege.”Trump, on the other hand, had made attempts during his presidency to repeal and replace the ACA, arguing that it provided “lousy healthcare.” While those efforts ultimately failed in the Senate, Trump succeeded in weakening the ACA by eliminating the individual mandate penalty through the 2017 Tax Cuts and Jobs Act.In a potential second term, Trump might renew efforts to dismantle or significantly alter the ACA. Although he has not presented a comprehensive replacement plan, he said during the Presidential debate held on September 9 that he has “concepts of a plan.”Drug prices: Harris to accelerate Medicare price cuts; Trump to focus on genericsHarris has had an aggressive stance on reducing prescription drug costs. Her tie-breaking vote on the Inflation Reduction Act gave Medicare the power to negotiate lower drug prices with pharmaceutical companies.Harris has pledged to accelerate those negotiations, once she becomes President, to cover more drugs and further lower prices for Americans. She also intends to extend the US$ 35 cap on insulin and the US$ 2,000 cap on out-of-pocket spending for seniors to all Americans, not just those on Medicare.Harris plans to make permanent the Biden-Harris tax credit enhancements that have already lowered healthcare premiums by an average of about US$ 800 a year for millions of Americans. This move would ensure continued accessibility to health insurance for a broader segment of the population.However, her stance on insurance companies and Big Pharma, including her support for “march-in” rights, might face resistance from pharmaceutical companies concerned about maintaining incentives for innovation.On the issue of drug pricing, Trump’s record is mixed. While he took credit for some decreases in prescription drug prices during his presidency, his administration’s most significant regulatory changes often favored pharmaceutical companies.Trump did issue a rule setting up a path to import drugs from Canada and other countries, but this initiative has faced significant hurdles, including pushback from Canadian authorities.Trump’s stance on drug pricing for a potential second term appears to focus on increasing generic and biosimilar competition, importing drugs made in the US but sold overseas back to the US, and capping out-of-pocket insulin costs. While he has criticized Big Pharma for putting profits above people, his administration’s policies had often aligned with industry interests.Harris appears committed to drug control; Trump had cut public health fundsMental health and substance abuse are the other areas where Harris has shown strong commitment. Having prosecuted drug traffickers, she has demonstrated her commitment to curbing the opioid epidemic.In the White House, she helped direct more than US$ 150 billion to disrupt the flow of illicit drugs and delivered billions of dollars in investments to states to fund lifesaving programs. Under a Harris administration, we might see increased funding for addiction treatment programs and continued efforts to make overdose-reversal drugs like naloxone more accessible.During his presidency, Trump had significantly reduced funding for public health programs. His administration had suggested budget cuts to the Centers for Disease Control and Prevention (CDC) and other public health agencies, justifying them as measures for fiscal responsibility.Our viewGiven her record, a Harris presidency could lead to increased insurance coverage. However, it might also come with increased regulation and price controls. More aggressive drug price negotiations could pressure pharmaceutical companies’ profit margins, potentially affecting R&D budgets. Stricter vigilance on the pharmaceutical industry could lead to more litigation and regulatory challenges for drug companies. But in the long run, this might also improve public trust in drug companies and in the healthcare systems.Under a second Trump term, reduced public health funding could create challenges for community health providers and public health initiatives. An emphasis on generic competition could pressure brand-name drug manufacturers, but create opportunities for generic drug makers.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 700

    https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices

    #Phispers by PHARMACOMPASS
    26 Sep 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    BMS skates again on $6.4B Celgene shareholder lawsuit
    BMS skates again on $6.4B Celgene shareholder lawsuit

    02 Oct 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/bms-skates-again-64b-celgene-shareholder-lawsuit-still-not-free-another-filing

    FIERCE PHARMA
    02 Oct 2024
    Share Share
    BMS pays Prime $110M to form T-cell therapy pact
    BMS pays Prime $110M to form T-cell therapy pact

    01 Oct 2024

    // PRESS RELEASE

    https://investors.primemedicine.com/news-releases/news-release-details/prime-medicine-announces-strategic-research-collaboration-and

    PRESS RELEASE
    01 Oct 2024
    Share Share
    US FDA approves Bristol Myers' schizophrenia drug
    US FDA approves Bristol Myers' schizophrenia drug

    27 Sep 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-bristol-myers-schizophrenia-drug-2024-09-26/

    REUTERS
    27 Sep 2024
    Share Share
    Bristol Myers Squibb Presents New Data On Sotyktu Efficacy
    Bristol Myers Squibb Presents New Data On Sotyktu Efficacy

    27 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240925005092/en

    BUSINESSWIRE
    27 Sep 2024
    Share Share
    BMS, 2seventy scrap Abecma trial in first-line multiple myeloma
    BMS, 2seventy scrap Abecma trial in first-line multiple myeloma

    26 Sep 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/bristol-myers-2seventy-scrap-abecma-first-line-myeloma-trial-citing-enrollment-challenges

    FIERCE PHARMA
    26 Sep 2024
    Share Share
    Experts back FDA's plan to restrict PD-1 drugs in GI cancers
    Experts back FDA's plan to restrict PD-1 drugs in GI cancers

    26 Sep 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/experts-support-fdas-plan-restrict-pd-1-drugs-uses-stomach-cancer-biomarker

    FIERCE PHARMA
    26 Sep 2024
    Share Share

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Bristol Myers Squibb and get a quotation

    Bristol Myers Squibb is a supplier offers 89 products (APIs, Excipients or Intermediates).

    Find a price of Tremelimumab bulk with DMF offered by Bristol Myers Squibb

    Find a price of 6-Aminopenicillanic Acid bulk offered by Bristol Myers Squibb

    Find a price of 7-Amino Cephalosporanic Acid bulk offered by Bristol Myers Squibb

    Find a price of 7-Aminodesacetoxycephalosporanic Acid bulk offered by Bristol Myers Squibb

    Find a price of Amikacin bulk offered by Bristol Myers Squibb

    Find a price of Amikacin Sulfate bulk offered by Bristol Myers Squibb

    Find a price of Amoxicillin Trihydrate bulk offered by Bristol Myers Squibb

    Find a price of Amphotericin B bulk offered by Bristol Myers Squibb

    Find a price of Ampicillin bulk offered by Bristol Myers Squibb

    Find a price of Ampicillin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Ampicillin Trihydrate bulk offered by Bristol Myers Squibb

    Find a price of Aripiprazole bulk offered by Bristol Myers Squibb

    Find a price of Benzylpenicillin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Calcium Amphomycin bulk offered by Bristol Myers Squibb

    Find a price of Carmustine bulk offered by Bristol Myers Squibb

    Find a price of Cefaclor bulk offered by Bristol Myers Squibb

    Find a price of Cefadroxil bulk offered by Bristol Myers Squibb

    Find a price of Cefazolin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Cephalexin bulk offered by Bristol Myers Squibb

    Find a price of Cephapirin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Cephradine bulk offered by Bristol Myers Squibb

    Find a price of Cloxacillin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Desonide bulk offered by Bristol Myers Squibb

    Find a price of Diethylstilbestrol bulk offered by Bristol Myers Squibb

    Find a price of Dimetridazol bulk offered by Bristol Myers Squibb

    Find a price of Enoxacin bulk offered by Bristol Myers Squibb

    Find a price of Fluphenazine bulk offered by Bristol Myers Squibb

    Find a price of Fluphenazine Decanoate bulk offered by Bristol Myers Squibb

    Find a price of Glucosamine Hydrochloride bulk offered by Bristol Myers Squibb

    Find a price of Halcinonide bulk offered by Bristol Myers Squibb

    Find a price of Hetacillin bulk offered by Bristol Myers Squibb

    Find a price of Hetacillin Potassium bulk offered by Bristol Myers Squibb

    Find a price of Hydroxyurea bulk offered by Bristol Myers Squibb

    Find a price of Insulin bulk offered by Bristol Myers Squibb

    Find a price of Irbesartan bulk offered by Bristol Myers Squibb

    Find a price of Isoniazid bulk offered by Bristol Myers Squibb

    Find a price of Kanamycin Sulfate bulk offered by Bristol Myers Squibb

    Find a price of Methicillin bulk offered by Bristol Myers Squibb

    Find a price of Nystatin bulk offered by Bristol Myers Squibb

    Find a price of Oxacillin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Penicillin G Potassium bulk offered by Bristol Myers Squibb

    Find a price of Penicillin V Potassium bulk offered by Bristol Myers Squibb

    Find a price of Pentamidine Isethionate bulk offered by Bristol Myers Squibb

    Find a price of Piperacillin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Piperazine bulk offered by Bristol Myers Squibb

    Find a price of Sodium Dicloxacillin bulk offered by Bristol Myers Squibb

    Find a price of Tetracycline Hydrochloride bulk offered by Bristol Myers Squibb

    Find a price of Tipredane bulk offered by Bristol Myers Squibb

    Find a price of Triamcinolone Acetonide bulk offered by Bristol Myers Squibb

    Find a price of Triamcinolone Diacetate bulk offered by Bristol Myers Squibb

    Find a price of Triamcinolone Hexacetonide bulk offered by Bristol Myers Squibb

    Find a price of Triflupromazine bulk offered by Bristol Myers Squibb

    Find a price of Vitamin B12 bulk offered by Bristol Myers Squibb

    Find a price of Warfarin Sodium bulk offered by Bristol Myers Squibb

    Find a price of TESTING FACILITIES FOR RAW MATERIALS & FINISHED GOODS bulk offered by Bristol Myers Squibb

    Find a price of FACILITIES FOR THE MFG. OF SEMISOLIDS IN HUMACAO, PUERTO RICO bulk offered by Bristol Myers Squibb

    Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-214) TO THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) bulk offered by Bristol Myers Squibb

    Find a price of MURINE MONOCLONAL ANTIBODY (ALPHA CTLA4) TOCTLA4 bulk offered by Bristol Myers Squibb

    Find a price of FACILITIES LOCATED IN MAYAGUEZ, PUERTO RICO bulk offered by Bristol Myers Squibb

    Find a price of MDX-1303 VALORTIM (TM), ANTI-BACILLUS ANTHRACIS PROTECTIVE ANTIGEN HUMAN MONOCLONAL ANTIBODY bulk offered by Bristol Myers Squibb

    Find a price of MANUFACTURE OF HYDROXYUREA bulk offered by Bristol Myers Squibb

    Find a price of PROLIXIN ELIXIR (FLUPHENAZINE HYDROCHLORIDE) bulk offered by Bristol Myers Squibb

    Find a price of JM-9 FOR INJECTION bulk offered by Bristol Myers Squibb

    Find a price of HYDROCHLORIDE 6484 R.P. (VET MED) bulk offered by Bristol Myers Squibb

    Find a price of PLASTIC CONTAINERS bulk offered by Bristol Myers Squibb

    Find a price of SUMMARIES OF THE BACKGROUND & QUALIFICATION OF INVEST & MONITORS bulk offered by Bristol Myers Squibb

    Find a price of DROCINONIDE PHOSPHATE POTASSIUM bulk offered by Bristol Myers Squibb

    Find a price of TRI-BUFFERED BUFFERIN bulk offered by Bristol Myers Squibb

    Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-070) TO PROSTATE SPECIFIC MEMBRANE ANTIGEN bulk offered by Bristol Myers Squibb

    Find a price of POT. MELARSONYL-mel W (TRIMELARSAN)-MFG, SPECS, & METH. OF ANALYSIS bulk offered by Bristol Myers Squibb

    Find a price of RICIN CONJUGATED MURINE MONOCLONAL ANTIBODY (MDX-RA) TO HUMAN LENS EPITHELIAL CELLS bulk offered by Bristol Myers Squibb

    Find a price of METHODS, FACILITIES, AND CONTROLS IN MAYAGUEZ, PUERTO RICO bulk offered by Bristol Myers Squibb

    Find a price of LISTING OF INDS bulk offered by Bristol Myers Squibb

    Find a price of MDX-1100 (ANTI-CXCL 10/ANTI-IP-10 HUMAN MONOCLONAL ANTIBODY) bulk offered by Bristol Myers Squibb

    Find a price of MDX-015 (ANTI-IL15 HUMAN MONOCLONAL ANTIBODY) bulk offered by Bristol Myers Squibb

    Find a price of PERSONNEL FOR PUERTO RICO PLANTS bulk offered by Bristol Myers Squibb

    Find a price of FORMULAS: RHODIAL & BOUQUET 5886 bulk offered by Bristol Myers Squibb

    Find a price of FACILITIES AND CONTROLS PERSONNEL FOR MANUFACTURE AND CONTROL bulk offered by Bristol Myers Squibb

    Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-067) TO HEPARANASE bulk offered by Bristol Myers Squibb

    Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-060) TO CD30 bulk offered by Bristol Myers Squibb

    Find a price of FACILITIES LOCATED IN BARCELONETA, PUERTO RICO - PREVIOUSLY AN ANTIBIOTIC FILE bulk offered by Bristol Myers Squibb

    Find a price of MURINE MONOCLONAL ANTIBODY (PM-81) TO HUMAN MYELOID DIFFERENTIATION ANTIGEN bulk offered by Bristol Myers Squibb

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES. bulk offered by Bristol Myers Squibb

    Find a price of MFG. ANALYTICAL SPECS. & METHODS OF ANALYSIS FOR MEL B (ARSOBAL) bulk offered by Bristol Myers Squibb

    Find a price of PATIENT STARTER PACKAGES bulk offered by Bristol Myers Squibb

    Find a price of TESTOLACTONE TABLETS, 250 MG bulk offered by Bristol Myers Squibb

    Find a price of PICCOLITE RESIN S 115 L bulk offered by Bristol Myers Squibb

    Find a price of BIS (2-HYDROXY-5-CHLORO PHENYL) SULFIDE bulk offered by Bristol Myers Squibb

    Find a price of COMPOUND SQ 21, 286 bulk offered by Bristol Myers Squibb

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search